LAVA Therapeutics N.V.
Potent anti-tumor activity against patient CLL, MM and AML cells by LAVA-051, a bispecific Vγ9Vδ2-T and type 1 NKT cell engager targeting CD1d
Apr. 9, 2021- By: Roeland Lameris;Roeland Lameris;Jurjen M Ruben1;Iris de Weerdt;Rob Roovers;Arnon P Kater;Thilo Riedl;Victoria Iglesias;Benjamin Winograd;Ton EP Adang
Courtesy ofLAVA Therapeutics N.V.
Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity
Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity
- CD1d can be expressed by several hematologic malignancies
- Bispecific Vγ9Vδ2-T cell engager
- Unique ability to also trigger type 1 natural killer T (NKT) cells
- LAVA-051: humanized CD1d-Vδ2 bsVHH
Most popular related searches